Pura Vida Investments’s Cytokinetics CYTK Stock Holding History

Pura Vida Investments’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-15,000	Closed	-$645K	–	42
2022 Q3	$12.6M	Buy	+15,000	New	+$722K	0.73%	39
2019 Q4	–	Sell	-188,096	Closed	-$2.14M	–	109
2019 Q3	$2.14M	Buy	+188,096	New	+$2.36M	0.37%	64

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Pura Vida Investments's CYTK Position: Q4 2022 in Review

Pura Vida Investments sold out of Cytokinetics (CYTK) in Q4 2022, closing a stake of 15,000 shares — an estimated $645K sold.

Pura Vida Investments first reported a position in CYTK in Q3 2019 and held it in 2 quarters. The position peaked at $12.6M in Q3 2022. 277 funds tracked by Wall St. Rank hold CYTK as of Q4 2022.

Pura Vida Investments reported no remaining Cytokinetics position as of Q4 2022 after selling out during the quarter.
Pura Vida Investments sold 15,000 Cytokinetics shares in Q4 2022, an estimated $645K.
Pura Vida Investments first reported a position in Cytokinetics in Q3 2019 and held it in 2 quarters.
Pura Vida Investments's Cytokinetics position peaked at $12.6M in Q3 2022.
277 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2022.

Based on Pura Vida Investments's 13F filing for Q4 2022, filed 14 Feb 2023.